| Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura M Scully, SR Cataland, F Peyvandi, P Coppo, P Knöbl, ... New England Journal of Medicine 380 (4), 335-346, 2019 | 762 | 2019 |
| Caplacizumab for acquired thrombotic thrombocytopenic purpura F Peyvandi, M Scully, JA Kremer Hovinga, S Cataland, P Knöbl, H Wu, ... New England Journal of Medicine 374 (6), 511-522, 2016 | 602 | 2016 |
| Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies M Scully, S Cataland, P Coppo, J De La Rubia, KD Friedman, JK Hovinga, ... Journal of thrombosis and haemostasis 15 (2), 312-322, 2017 | 424 | 2017 |
| Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia G Marcucci, JC Byrd, G Dai, MI Klisovic, PJ Kourlas, DC Young, ... Blood, The Journal of the American Society of Hematology 101 (2), 425-432, 2003 | 316 | 2003 |
| Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial F Fakhouri, M Hourmant, JM Campistol, SR Cataland, M Espinosa, ... American journal of kidney diseases 68 (1), 84-93, 2016 | 302 | 2016 |
| ISTH guidelines for treatment of thrombotic thrombocytopenic purpura XL Zheng, SK Vesely, SR Cataland, P Coppo, B Geldziler, A Iorio, ... Journal of Thrombosis and Haemostasis 18 (10), 2496-2502, 2020 | 273 | 2020 |
| ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura XL Zheng, SK Vesely, SR Cataland, P Coppo, B Geldziler, A Iorio, ... Journal of Thrombosis and Haemostasis 18 (10), 2486-2495, 2020 | 208 | 2020 |
| Leukocytoreduction for acute leukemia P Porcu, S Farag, G Marcucci, SR Cataland, MS Kennedy, M Bissell Therapeutic apheresis 6 (1), 15-23, 2002 | 202 | 2002 |
| Venous thromboembolic disease MB Streiff, PL Bockenstedt, SR Cataland, C Chesney, C Eby, J Fanikos, ... Journal of the National Comprehensive Cancer Network 11 (11), 1402-1429, 2013 | 196 | 2013 |
| Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management S Sukumar, B Lämmle, SR Cataland Journal of clinical medicine 10 (3), 536, 2021 | 173 | 2021 |
| Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse M Jin, TC Casper, SR Cataland, MS Kennedy, S Lin, YJ Li, HM Wu British journal of haematology 141 (5), 651-658, 2008 | 162 | 2008 |
| Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura XL Zheng, HM Wu, D Shang, E Falls, CG Skipwith, SR Cataland, ... Haematologica 95 (9), 1555, 2010 | 152 | 2010 |
| The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment E Rondeau, M Scully, G Ariceta, T Barbour, S Cataland, N Heyne, ... Kidney international 97 (6), 1287-1296, 2020 | 148 | 2020 |
| International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related … M Scully, S Cataland, P Coppo, J de la Rubia, KD Friedman, ... J Thromb Haemost 15 (2), 312-322, 2017 | 136 | 2017 |
| How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome SR Cataland, HM Wu Blood, The Journal of the American Society of Hematology 123 (16), 2478-2484, 2014 | 134 | 2014 |
| Myeloid growth factors J Crawford, J Armitage, L Balducci, PS Becker, DW Blayney, SR Cataland, ... Journal of the National Comprehensive Cancer Network 11 (10), 1266-1290, 2013 | 132 | 2013 |
| Redefining outcomes in immune TTP: an international working group consensus report A Cuker, SR Cataland, P Coppo, J de La Rubia, KD Friedman, JN George, ... Blood, The Journal of the American Society of Hematology 137 (14), 1855-1861, 2021 | 129 | 2021 |
| Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP SR Cataland, VM Holers, S Geyer, S Yang, HM Wu Blood, The Journal of the American Society of Hematology 123 (24), 3733-3738, 2014 | 126 | 2014 |
| Venous thromboembolic disease: Clinical practice guidelines in Oncology™ LD Wagman, MF Baird, CL Bennett, PL Bockenstedt, SR Cataland, ... JNCCN Journal of the National Comprehensive Cancer Network 4 (9), 838-869, 2006 | 125* | 2006 |
| Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura F Peyvandi, M Scully, JAK Hovinga, P Knöbl, S Cataland, K De Beuf, ... Journal of Thrombosis and Haemostasis 15 (7), 1448-1452, 2017 | 113 | 2017 |
